Share Prices & Company Research

Stockbroking

Indivior

Current Price 104.80p Bid 104.80p Ask 105.80p Change -11.41%
Last Updated: 19/02/2019 19:42. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Indivior plc is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline Focus on you makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide.

Financial Highlights Year Ended 31/12/2018

Turnover
£1,005.00m
Operating Profit
£292.00m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
2.98

Key Personnel

Shaun Thaxter
Chief Executive Officer
Mark Wesley Crossley
Chief Financial Officer
Howard H Pien
Executive Chairman
Lorna Mary Southcombe Parker
Non-Executive Director
Daniel Joseph Phelan
Non-Executive Director
Lizabeth Herbst Zlatkus
Non-Executive Director
Daniel Tasse
Non-Executive Director
Christian Stanton Schade
Non-Executive Director
Dr Andrew Thomas McLellan
Non-Executive Director
Tatjana Anni Hilde May
Non-Executive Director
Dr Yvonne Greenstreet
Non-Executive Director

Stock Details

EPIC
INDV
ISIN
GB00BRS65X63
Shares in Issue
728,771,702
Market cap
£826.06m

Analyst Views (2)

Strong Buy
 
0.00%
Buy
 
0.00%
Hold
 
100.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
104.80p
Bid Price
104.80p
Ask Price
105.80p
Volume
5985163
Change Today
-13.50p
% Change Today
-11.41%
Open
115.80p
Previous Close
104.80p
Intraday High
119.25p
Intraday Low
104.80p
52 Week High
504.60p
52 Week Low
75.48p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Indivior Intra-day Chart

Indivior News

News in this section is provided by AJ Bell

Indivior's opioid addiction treatment meets primary, secondary goals 19 Feb 2019 | 09:19 Broker Forecast - Jefferies International issues a broker note on Indivior Plc 18 Feb 2019 | 10:20 Indivior cost cuts help boost profits; warns of 'imminent' risk from copycat products 14 Feb 2019 | 09:09 FTSE fails to follow Wall Street higher 12 Feb 2019 | 16:48 Global equities rise after new deal cuts likelihood of another US government shutdown 12 Feb 2019 | 12:01 UK stocks open 0.5% stronger amid US shutdown progress 12 Feb 2019 | 09:02 Indivior wary of rivals launching copycat products after US court setback 12 Feb 2019 | 07:45 Global equities gain momentum despite weak European services data 05 Feb 2019 | 16:55 FTSE gains momentum on BP beat and weaker sterling 05 Feb 2019 | 12:02 UK stocks open 0.9% stronger, buoyed by BP beat 05 Feb 2019 | 09:04 Indivior fails to overturn decision preventing rival from selling copycat product 05 Feb 2019 | 08:13 Global equities gain momentum ahead of Google update 04 Feb 2019 | 16:56 FTSE firms above 7,000 as construction malaise dogs sterling 04 Feb 2019 | 12:03 FTSE off to quiet start as Brexit outcome remains elusive 04 Feb 2019 | 09:07 Indivior sells rights to opioid addiction treatment in China for up to $112.5m 04 Feb 2019 | 07:13 FTSE fails to follow US and European equities higher amid stronger sterling 25 Jan 2019 | 17:04 Sterling strength caps FTSE gains 25 Jan 2019 | 12:12 Indivior granted restraining order to temporarily stop Alvogen from launching copycat drugs 25 Jan 2019 | 07:21 Falling oil prices and National Grid woes hit FTSE 100 18 Dec 2018 | 16:42 Broker Forecast - RBC Capital Markets issues a broker note on Indivior Plc 12 Dec 2018 | 10:20 US Court denies Indivior's rival request to immediately begin selling copycat drug 12 Dec 2018 | 08:17 Indivior cuts debt load by $85m 30 Nov 2018 | 15:08 Indivior to provide update on plans, strategy on Dec. 18 27 Nov 2018 | 08:12 Oil supply concerns hit the FTSE 100 23 Nov 2018 | 16:53 Indivior's opioid addiction treatment gets regulatory nod in Canada 23 Nov 2018 | 07:28 FTSE climbs on rising oil majors 21 Nov 2018 | 16:47 Stronger oil prices drive FTSE 100 higher 21 Nov 2018 | 12:03 Broker Forecast - RBC Capital Markets issues a broker note on Indivior Plc 21 Nov 2018 | 09:50 Indivior maintains outlook but warns rival's launch of generic product would hurt profits 21 Nov 2018 | 08:42 FTSE slips on Brexit and trade war fears 20 Nov 2018 | 17:02

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Tangible Assets
57.0
54.0
Intangible Assets & Goodwill
84.0
92.0
Investments & Other Non-Current Assets
77.0
73.0
Total Non-Current Assets
218.0
219.0
Inventory
78.0
52.0
Trade & Receivables
287.0
278.0
Cash & Receivables
924.0
863.0
Other Current Assets & Assets Held for Resale
40.0
32.0
Total Assets
1,547.0
1,444.0

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Short Term Liabilities
818.0
854.0
Long Term Liabilities
663.0
793.0
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
1,481.0
1,647.0

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Net Assets
66.0
-203.0

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Share Capital
73.0
72.0
Minority Interests
0.0
0.0
Retained Earnings
1,315.0
1,032.0
Share Premium Account
5.0
2.0
Other Equity
-1,327.0
-1,309.0
Total Equity
66.0
-203.0

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Cashflow from Operating Activities
303.0
295.0
Cashflow Before Financing
307.0
252.0
Increase / Decrease in Cash
62.0
168.0

Income (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Turnover
1,005.0
1,093.0
Cost of Sales
128.0
104.0
Gross Profit
877.0
989.0
Operating Profit
292.0
193.0
Pre-Tax Profit
278.0
137.0
Profit / Loss for the Year
275.0
58.0

Dividend History

Data has been provided by AJ Bell

Period
Ex-Dividend Date
Payment Date
H2 Dividend
16 Jun 2016
29 Jul 2016
H1 Dividend
17 Sep 2015
23 Oct 2015
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.